Upregulation of S100A9 contributes to the acquired resistance to BRAF inhibitors

Backgrounds Acquired resistance is a significant clinical challenge in targeted therapy of melanomas using BRAF inhibitors. We previously identified that downregulation of miR-92a-1-5p confers acquired resistance to BRAF inhibition using an miRNA array platform.